Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCLL.L Regulatory News (CLL)

  • There is currently no data for CLL

Launch of CSR programme

13 Mar 2012 07:00

RNS Number : 2001Z
Cello Group plc
13 March 2012
 



13 March 2012

 

Cello Group plc

 

Launch of CSR programme

 

Cello Group plc (AIM:CLL, 'Cello', or 'the Group'), the insight and strategic marketing group, has today launched its new Corporate Social Responsibility programme 'Talking Taboos'. 

 

Talking Taboos is a campaigning brand that aims to directly tackle health and social issues using Cello's experience and resources in the healthcare space. It will focus on areas where embarrassment, fear or ignorance prevents sufferers from seeking help.

 

For 2012, Talking Taboos will be addressing teen mental health, specifically self-harm, through an extensive research project with the teen charity YoungMinds. The research will examine the context in which teenagers find themselves when actively self-harming, and will attempt to inform parents, teachers, peers and health professionals how best to identify and support at-risk and self-harming teens.

Each Cello Group company will utilise its expertise in methodology or market sector to contribute to a 'whole community' view that will help carers and sufferers by providing context, exploding myths and challenging prevailing attitudes to self-harm. The programme is being led by Vincent Nolan, Group Chairman of Cello Research and Consulting, and the Group is planning to expand this initiative in the future to assist organisations which address a range of health related issues.

Mark Scott, Cello Group CEO, said:

 

"Talking Taboos is a great opportunity for us to support a worthwhile cause in the best way we know how - through our market leading research and our wealth of experience in working with health issues.

 

"It is also an ideal way for our companies to demonstrate their abilities and talents and work across the group to deliver a comprehensive project that should help change the way that self-harm is perceived and handled."

 

 

Enquiries:

 

Cello Group plc (www.cellogroup.com)

Mark Scott, Chief Executive

020 7812 8460

Mark Bentley, Group Finance Director

Vincent Nolan, Group Chairman - Cello Research and Consulting

020 7655 9900

Cenkos

Bobbie Hilliam

020 7397 8900

College Hill

Kay Larsen/Rozi Morris

020 7457 2020

 

 

Notes to Editors (www.cellogroup.com)

 

Cello is an insight and strategic marketing group.

 

The Group's strategy is to create value for shareholders by building an international research and consulting business able to advise blue chip clients globally, along with a marketing business capable of delivering world class solutions.

 

Cello has annualised revenues in excess of £130m, annualised gross profit in excess of £65m and employs over 700 professional staff.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAGGUUWWUPPGMP
Date   Source Headline
5th Jun 20181:24 pmRNSBlock listing Interim Review
29th May 20183:45 pmRNSDirector/PDMR Dealings and Total Voting Rights
9th May 20181:14 pmRNSResult of AGM
9th May 20187:00 amRNSAGM Statement
30th Apr 20182:58 pmRNSTotal Voting Rights
26th Apr 20189:45 amRNSChange of Name
25th Apr 20184:45 pmRNSChange of Name update
23rd Apr 201810:28 amRNSChange of name to Cello Health Group plc
16th Apr 20189:30 amRNSAnnual Report and Notice of AGM
22nd Mar 20187:00 amRNSFinal Results
27th Feb 20183:38 pmRNSTotal Voting Rights
18th Jan 20187:00 amRNSPre Close Trading Statement
23rd Nov 20173:54 pmRNSHolding(s) in Company
31st Oct 201711:16 amRNSTotal Voting Rights
26th Oct 20172:37 pmRNSDirector/PDMR Shareholding
29th Sep 20173:43 pmRNSGrant of Options
27th Sep 20174:59 pmRNSDirector/PDMR Shareholding
22nd Sep 201712:05 pmRNSDirector/PDMR Shareholding
20th Sep 20173:58 pmRNSHolding(s) in Company
20th Sep 201711:52 amRNSAdditional Block Listing of Ordinary Shares
20th Sep 20177:00 amRNSInterim Results
31st Aug 20173:19 pmRNSTotal Voting Rights
31st Jul 20173:06 pmRNSTotal Voting Rights
19th Jul 20177:00 amRNSPre Close Trading Statement
18th Jul 20177:00 amRNSAcquisition of Advantage Healthcare Inc
30th Jun 201712:31 pmRNSTotal Voting Rights
23rd Jun 201712:23 pmRNSHolding(s) in Company
14th Jun 201711:33 amRNSDirector/PDMR Shareholding
31st May 201710:27 amRNSTotal Voting Rights
18th May 20172:13 pmRNSHolding(s) in Company
10th May 20175:18 pmRNSHolding(s) in Company
9th May 20172:55 pmRNSResult of AGM
9th May 20177:00 amRNSAGM Statement
2nd May 20173:15 pmRNSIssue of Equity
13th Apr 20172:40 pmRNSAnnual Report and notice of Annual General Meeting
4th Apr 20175:44 pmRNSBlock listing Interim Review
31st Mar 201710:43 amRNSTotal Voting Rights
28th Mar 20173:03 pmRNSHolding(s) in Company
22nd Mar 20177:00 amRNSPreliminary Results
21st Feb 20171:30 pmRNSHolding(s) in Company
20th Feb 20173:19 pmRNSHolding(s) in Company
20th Feb 20179:29 amRNSTotal Voting Rights
17th Feb 201710:40 amRNSResult of General Meeting
1st Feb 20177:00 amRNSPlacing & Acquisition of Defined Health
19th Jan 20177:00 amRNSPre close trading statement
31st Oct 20163:58 pmRNSTotal Voting Rights
28th Oct 201611:37 amRNSDirector/PDMR Shareholding
12th Oct 20167:00 amRNSDirectorate Change
5th Oct 20164:32 pmRNSDirector/PDMR Shareholding
23rd Sep 20165:30 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.